Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
A multinational research collaboration has developed a new peptide dubbed “PATAS”, which appears to fix the metabolic abnormalities leading to type 2 diabetes (T2D).
Early data from Amgen’s ongoing trial on Lumakras for non-small cell lung cancer hinted at positive results from what could be a transformative combination of drugs versus cancer.
BioSpace takes a look at some of the recent legal battles and settlements related to the opioid epidemic across the industry.
Physicians at New York University have successfully implanted pig hearts into the bodies of patients that were living but no longer showed neural function, a process called xenotransplantation.
An NIH-sponsored trial assessing a combination of Humanigen’s lenzilumab and Gilead Sciences’ remdesivir in hospitalized COVID-19 patients failed to achieve the primary endpoint.
Sanofi, Certara, Pfizer and Thermo Fisher are facing hiring challenges head-on with a common strategy: upskilling programs. They use these programs to fill open roles while training and retaining existing talent.
In what seems like an unlikely collaboration, Seattle-based Fred Hutchinson Cancer Center (Fred Hutch) is partnering with Amazon to develop cancer vaccines.
Atara announced that it has completed an interim analysis of its Phase II EMBOLD trial for the use of its candidate ATA188 in patients with progressive multiple sclerosis.
The pace of unicorn creation – which is still quite fast – is slowing as economists predict a coming recession. BioSpace sought out the perspective of four experts.
Aldeyra Therapeutics announced results from a crossover clinical trial, showing that its drug candidate reproxalap was effective in improving ocular redness and tear production in patients with dry eye disease.
Moderna has dosed its first participant in a Phase I clinical trial of mRNA-1215, a vaccine designed to fight the Nipah virus (NiV), a virus contracted in humans through animals.
Annexon and Pliant Therapeutics both made efforts to secure additional financing to support their R&D endeavors.